Uncomplicated urinary tract infections, what about fosfomycin and nitrofurantoin in 2006?;Quelle sensibilité aux antibiotiques pour les bactéries responsables d'infections urinaires ? Que penser de fosfomycine et nitrofuranes ?

Pathologie Biologie

Volumn 54, Issue 8-9 SPEC.ISS., 2006, Pages 462-466

  Honderlick, P ^a   Cahen, P ^a   Gravisse, J ^a   Vignon, D ^a  

^a FOCH HOSPITAL   (France)

Author keywords

Fluoroquinolones; Fosfomycine; Nitrofurantoin; Uncomplicated urinary tract infection

Indexed keywords

AMOXICILLIN; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; FOSFOMYCIN; NALIDIXIC ACID; NITROFURANTOIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAMOPLANIN; TROMETAMOL; ANTIINFECTIVE AGENT; NITROFURAN DERIVATIVE; URINARY TRACT ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG POTENCY; DRUG SENSITIVITY; HUMAN; IN VITRO STUDY; PREVALENCE; TREATMENT INDICATION; URINARY TRACT INFECTION; DRUG EFFECT; ESCHERICHIA COLI; FRANCE; MICROBIOLOGICAL EXAMINATION;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, URINARY; ESCHERICHIA COLI; FOSFOMYCIN; FRANCE; HUMANS; MICROBIAL SENSITIVITY TESTS; NITROFURANS; PREVALENCE; URINARY TRACT INFECTIONS;

EID: 33750815974     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2006.07.016     Document Type: Article

References (14)

1. Sirot J., Nicolas-Chanoine M.H., Chardon H., Avril J.L., Cattoen C., et al. Susceptibility of Enterobacteriaceae to β-lactam agents and fluoroquinolones: a 3-year survey in France. CMI 8 (2002) 207-213
2. Ungheri D., Albani E., and Belluco G. In vitro susceptibility of quinolone-resistant clincal isolates of Escherichia coli to fosfomycin trometalol. J. Chemother. 14 (2002) 237-240
3. Fadda G., Nicoletti G., Schito G.C., and Tempera G. Antimicrobial susceptibility patterns from uncomplicated urinary tract infections isolated in a multicenter italian survey: possible impact on guidelines. J. Chemother. 17 (2005) 251-257
4. Farrell D.J., Morrissey I., De Rubeis D., Robbins M., and Felmingham D.A. UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infections. J. Infect. 46 (2003) 94-100
5. Gordon K.A., and Jones R.N. Sentry participant Groups (Europe, Latin America,North America). Diagn. Microbiol. Infect. Dis. 45 (2003) 295-301
6. Kahlmeter G. Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study. Int. J. Antimicrob. Agents suppl 2 (2003) 49-52
7. Kahan N.R., Chinitz D.P., Waitman D.A., and Kahan E. Empiric treatment of uncomplicated UTI in women: wasting money when more is not better. J. Clin. Pharm. Ther. 29 (2004) 437-441
8. Arslan H., Azap O.K., Ergonul O., Timurkaynak F., et al. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from communuty acquired urinary tract infections in Turkey. J. Antimicrob. Chemother. 56 (2005) 914-918
9. Alos J.-L., Serrano M.-G., Gomez-Garces J.-L., and Perianes J. Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections in relation to demographic and clinical data. CMI 11 (2005) 199-203
10. Sotto A., Merle De Boever C., Fabro-Perray P., Gouby A., Sirot D., and Jourdan J. Risk factors for antibiotic-resistant Escherichia coli isolated from hospitalised patients with urinary tract infections: a prospective study. J. Clin. Microbiol. 39 (2001) 438-444
11. Schitto G.C. Why fosfomycine trometalol as first line therapy for uncomplicated UTI?. Int. J. Antimicrob. Agents suppl 2 (2003) 79-83
12. Nickel J.C. Management of urinary tract infections: historical perspective and current strategies: Part 2 -Modern management. J. Urol. 173 (2005) 27-32
13. Grude N., Tveten Y., Jenkins A., and Kristiansen B.E. Uncomplicated urinary tract infections. Bacterial findings and efficacy of empirical antibacterial treatment. Scand. J. Prim. Health Care 23 (2005) 115-119
14. Komp Lindgren P., Marcusson L.L., Sandvang D., Frimodt-Moller N., and Hughes D. Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. AAC 49 (2005) 2343-2351